Cardiometabolic health

Probiotics for cardiometabolic health

Cardiometabolic health

Healthy gut, happy heart

Science shows that the gut bacteria may influence several molecules linked to lipid metabolism, which is closely linked to cholesterol 1,2,3,4

We have characterized the mechanism of action in our probiotic solutions to deliver targeted cardiometabolic health solutions – proven to support healthy cholesterol and safe weight management.

Probiotic solutions for Cardiometabolic health

KABP® Cardio

1.2 billion CFU/dose

Kaneka Probiotics’ Cardio is an IP-protected and patented probiotic formulation developed to improve the metabolism of cholesterol in the blood. Its formulation contains three clinical strains and there have been two published clinical trials (randomized, double-blind, placebo-controlled design).

These specific, triple Lactobacillus plantarum strains showed a robust capability to sur­vive under harsh gastrointestinal tract (GI) conditions, including exposures to acids and bile. In addition, these specific strains were demonstrated to adhere to intestinal epithe­lial cells. In terms of lipid metabolism, the strains showed a particular ability to produce large amounts of bile salt hydrolase. Bile salts are responsible for recirculating choles­terol systemically. By hydrolyzing the bile-salt molecule, which contains cholesterol, the re-uptake of cholesterol into the body is impacted.

Indications

  • Promotes heart health
  • Supports healthy total cholesterol, LDL and HDL levels already in the normal range
  • Helps maintain cholesterol levels already in the normal range in healthy individuals
  • Maintains a healthy triglyceride level already in the normal range
  • FDA GRAS certified

Probiotic Strains

  • L. plantarum KABP® 011
  • L. plantarum KABP® 012
  • L. plantarum KABP® 013

Formats

Capsules, sticks, drops

Clinical Evidence

Tang, W. H. W., Kitai, T. & Hazen, S. L. Gut microbiota in cardiovascular health and disease. Circulation Research vol. 120 1183–1196 (2017).

Herrema, H, Nieuwdorp, M. & Groen, A. K. Microbiome and Cardiovascular Disease. Handb Exp Pharmacol (2020).

Karlsson, F. H. et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat. Commun. 3, (2012).

Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: Human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).

Dora IA et al. “Effects of Consumption of Probiotics and Prebiotics on Serum Lipid Levels in Humans”. Critical Reviews in Biochemistry and Molecular Biology 37(4) (2002), 259- 281.

Fuentes, Mari C., et al. “Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults.” British Journal of Nutrition 109.10 (2013): 1866-1872.

Fuentes, Mari C., et al. “A randomized clinical trial evaluating a proprietary mixture of Lactobacillus plantarum strains for lowering cholesterol1.” Mediterranean Journal of Nutrition and Metabolism, vol. 9, no. 2, pp. 125-135, 2016.

Jumangit, et al. “An observational, prospective study to determinate the efficacy and safety of AB-LIFE.” Poster presentation.

Tang, W. H. W., Kitai, T. & Hazen, S. L. Gut microbiota in cardiovascular health and disease. Circulation Research vol. 120 1183–1196 (2017).

Herrema, H, Nieuwdorp, M. & Groen, A. K. Microbiome and Cardiovascular Disease. Handb Exp Pharmacol (2020).

Karlsson, F. H. et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat. Commun. 3, (2012).